Large spending on clinical research projects in a foreign country can expose life science companies to potentially millions in foreign currency risks. A successful clinical research relationship may depend on rigorous risk-hedged planning and management.
Hear SVB's Life Science and Foreign Exchange teams engage in a dialogue covering:
- How to leverage SVB's insight and solutions to improve contract economics
- Case studies of how FX hedging and negotiation tactics can affect the bottom line
- Common contractual terms to be aware of when negotiating with clinical research organizations
- Advantages of negotiating in USD or investigator’s local currency
This article is intended for US audiences only.